Skip to main content
. 2016 Jul 22;5(7):e003515. doi: 10.1161/JAHA.116.003515

Figure 2.

Figure 2

Forest plot of individual and summarized odds ratios for the comparison of bivalirudin vs heparin in STEMI patients for (A) major bleeding at 30 days, (B) acute stent thrombosis, (C) all‐cause mortality at 30 days, and (D) cardiac mortality at 30 days. BRAVE 4, Bavarian Reperfusion Alternatives Evaluation 4; BRIGHT, Bivalirudin in Acute Myocardial Infarction versus Heparin and GPI Plus Heparin; EUROMAX, European Ambulance Acute Coronary Syndrome Angiography; HEAT‐PPCI, How Effective are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention; HORIZONS‐AMI, Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction; MATRIX, Minimizing Adverse Hemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox; M‐H, Mantel‐Haenszel; STEMI, ST‐segment‐elevation myocardial infarction.